Article Text

other Versions

PDF
Incidental detection of germline variants of potential clinical significance by massively parallel sequencing in haematological malignancies
  1. Costas K Yannakou1,2,
  2. Kate Jones1,
  3. Georgina L Ryland1,
  4. Ella R Thompson1,2,
  5. Gareth Reid1,
  6. Michelle McBean1,
  7. Alison Trainer1,2,
  8. David Westerman1,2,
  9. Piers Blombery1,2
  1. 1Peter MacCallum Cancer Centre, Melbourne, Australia
  2. 2University of Melbourne, Melbourne, Australia
  1. Correspondence to Dr Costas K Yannakou, Department of Molecular Haematology, Pathology – Level 4, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne VIC 3000, Australia; costas.yannakou{at}petermac.org

Abstract

Massively parallel sequencing (MPS) technology has become routinely available for diagnosis, prognostication and therapeutic decision-making in haematological malignancies. However, increased throughput and wider coverage of genes can have unintended consequences. Germline variants of potential clinical significance (GVPCSs) detected during cancer testing may have implications for patients and families beyond the biological evaluation of a specific tumour. 721 reports generated from MPS panels used in the routine testing of myeloid and lymphoid malignancies were reviewed and variants within genes of potential germline relevance (TP53, RUNX1, GATA2 and WT1 in all contexts and CBL, KRAS and NRAS in the setting of juvenile myelomonocytic leukaemia) were analysed. A variant allele fraction threshold of ≥33.09% for considering germline origin of variants within cancer samples was established. The detection rate of incidental, pathogenic germline variants was 0.42%. Patient education and confirmatory germline sample testing of GVPCSs in appropriate circumstances are recommended.

  • haematopathology
  • haemato-oncology
  • cancer genetics
  • inherited pathology
View Full Text

Statistics from Altmetric.com

Footnotes

  • Handling editor Mary Frances McMullin.

  • Contributors CKY collected data, analysed data and drafted the manuscript. GLR collected data. PB, MM, KJ and GLR analysed data. All authors reviewed and approved the manuscript.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.